Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Other Non-Current Liabilities (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Other Non-Current Liabilities data on record, last reported at $409500.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 27.12% year-over-year to $409500.0; the TTM value through Sep 2025 reached $409500.0, up 27.12%, while the annual FY2024 figure was $359250.0, 35.53% down from the prior year.
  • Other Non-Current Liabilities reached $409500.0 in Q3 2025 per COEP's latest filing, down from $467250.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.0 million in Q2 2023 and bottomed at $88125.0 in Q1 2025.
  • Average Other Non-Current Liabilities over 4 years is $650062.5, with a median of $458625.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: surged 231.25% in 2023, then crashed 83.13% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $1.1 million in 2022, then tumbled by 50.47% to $557250.0 in 2023, then tumbled by 35.53% to $359250.0 in 2024, then increased by 13.99% to $409500.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $409500.0 in Q3 2025, $467250.0 in Q2 2025, and $88125.0 in Q1 2025.